Hyperfine, Inc.HYPR

Hyperfine, Inc. posted its second-highest quarterly revenue in the three months to 31 March 2026, hitting $3.9 million and up 83% year-over-year, but the company still lost $8.6 million in the same period and burned $9.0 million of operating cash. The Swoop® Portable MR Imaging® system may be the darling of the medical-tech set, but the balance sheet is still running on fumes, with $40.8 million in cash and equivalents and liabilities of $26.0 million leaving little room for error. (source: HYPR SEC EDGAR 10-Q (2026-05-12), https://www.sec.gov/Archives/edgar/data/1833769/000119312526219428/hypr-20260331.htm)

The company’s promise is portable, AI-powered MRI brain imaging delivered at the point of care, a feat it markets under the slogan “bringing brain imaging to the patient.” Yet the latest 10-Q shows a customer roster so concentrated that three clients alone accounted for the majority of revenue in Q1 2026, with revenues of $521k, $508k and $461k respectively. Leasing revenues, while material, sit outside the headline “revenue from contracts with customers” under ASC 842, so the commercial engine’s headline growth is less diversified than the brochures suggest. (source: HYPR SEC EDGAR 10-Q (2026-05-12), https://www.sec.gov/Archives/edgar/data/1833769/000119312526219428/hypr-20260331.htm)

On the operations side, Hyperfine carried $6.3 million of inventory at 31 March 2026, down $763k from the prior quarter, while capex for plant and equipment totalled a modest $242k over the same period. The company’s latest FDA clearance-Optive AI diffusion imaging-adds polish to the product story, but the cash-burn math remains stark: diluted loss per share of $0.09 on 97.7 million shares. Equity stood at $34.4 million against liabilities of $26.0 million, leaving a thin equity cushion over liabilities and a balance sheet that still looks more “venture-backed healthcare startup” than “mature imaging business.” (source: HYPR SEC EDGAR 10-Q (2026-05-12), https://www.sec.gov/Archives/edgar/data/1833769/000119312526219428/hypr-20260331.htm)

Hyperfine’s product rail emphasises the Swoop system’s global mission, with commercial availability and worldwide research partnerships highlighted on the company’s site. The evidence includes regulatory clearances and commercial availability statements, but the filings do not yet show broad geographic revenue distribution or a clear path to profitability beyond the current concentration risk. (source: Hyperfine, Inc. and the Swoop® Portable MR Imaging® System, https://www.hyperfine.io/; Expanding Access to Brain Imaging Worldwide, https://www.hyperfine.io/global)

The company’s latest press release boasts “over 80% year-over-year revenue growth” and positions the Swoop system as the first FDA-cleared AI-powered portable MR brain imaging device. What the filing shows, however, is that the top line is still dominated by a handful of customers while the bottom line remains in the red. The gap between the polished platform story and the filed numbers is now the most interesting part of the file. (source: Press Release dated May 12, 2026, https://www.sec.gov/Archives/edgar/data/1833769/000119312526219380/hypr-ex99_1.htm)